These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
290 related items for PubMed ID: 7744549
1. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Int J Neurosci; 1994 Nov; 79(1-2):21-45. PubMed ID: 7744549 [Abstract] [Full Text] [Related]
3. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids. Amaral AU, Wajner M. Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033 [Abstract] [Full Text] [Related]
15. Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. Wang XL, Li CJ, Xing Y, Yang YH, Jia JP. J Inherit Metab Dis; 2015 Sep; 38(5):855-61. PubMed ID: 25653144 [Abstract] [Full Text] [Related]
17. Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates. Skvorak K, Liu J, Kruse N, Mehmood R, Das S, Jenne S, Chng C, Lao UL, Duan D, Asfaha J, Du F, Teadt L, Sero A, Ching C, Riggins J, Pope L, Yan P, Mashiana H, Ismaili MHA, McCluskie K, Huisman G, Silverman AP. J Inherit Metab Dis; 2023 Nov; 46(6):1089-1103. PubMed ID: 37494004 [Abstract] [Full Text] [Related]
18. Clues and challenges in the diagnosis of intermittent maple syrup urine disease. Pode-Shakked N, Korman SH, Pode-Shakked B, Landau Y, Kneller K, Abraham S, Shaag A, Ulanovsky I, Daas S, Saraf-Levy T, Reznik-Wolf H, Vivante A, Pras E, Almashanu S, Anikster Y. Eur J Med Genet; 2020 Jun; 63(6):103901. PubMed ID: 32151765 [Abstract] [Full Text] [Related]